Tumor-Associated T-Lymphocytes and Macrophages are Decreased in Endometrioid Endometrial Carcinoma with MELF-Pattern Stromal Changes
Tóm tắt
Microcystic, elongated, fragmented (MELF)-pattern is an unusual morphology of myometrial invasive front in endometrioid endometrial carcinoma (EA). The aim of the study was to investigate potential correlation between MELF-pattern and peritumoral inflammatory immune response. A total of 96 out of 368 patients were included in this study. CD3, CD20, CD57. CD68 and S100 markers were used for the detection of tumor-associated T-lymphocytes (TAT), tumor-associated B-lymphocytes (TAB), tumor-associated NK-lymphocytes (NK), tumor-associated macrophages and dendritic cells respectively. Mann-Whitney tests, receiver operating characteristic (ROC) curve analysis, and Spearman correlation were used as methods for statistical analyses. Odds ratio with 95% confidence interval (95% CI) was determined with the use of a logistic regression model. A p < 0.05 was considered statistically significant. Our results suggested that the number of CD3 and CD68 cells were significantly lower (p < 0.001) in cases of endometrioid carcinoma with MELF-pattern. A significant correlation between the presence of MELF-pattern and decrease of CD3 positive T-lymphocytes (r = 0.691; p < 0.001) was also observed. Additionally, we found an inverse correlation between the presence of MELF-pattern and TAM (r = 0.568; p = 0.001). Therefore, our data suggest that MELF-pattern may be associated with EA stroma fibrosis that contains immune cells infiltration and demonstrated a decrease in the number of TAT and TAM cells. This may indicate the poor clinical prognosis of this disease.
Tài liệu tham khảo
Kojiro-Sanada S, Yasuda K, Nishio S et al (2017) CXCL14-CXCR4 and CXCL12-CXCR4 axes may play important roles in the unique invasion process of endometrioid carcinoma with MELF-pattern myoinvasion. Int J Gynecol Pathol 36:530–539. https://doi.org/10.1097/pgp.0000000000000362
Naki MM, Oran G, Tetikkurt SÜ et al (2017) Microcystic, elongated and fragmented (MELF) pattern of invasion in relation to histopathological and clinical prognostic factors in endometrioid endometrial adenocarcinoma. Journal of the Turkish-German Gynecological Association. https://doi.org/10.4274/jtgga.2017.0016
Kihara A, Yoshida H, Watanabe R et al (2017) Clinicopathologic association and prognostic value of microcystic, elongated, and fragmented (MELF) pattern in endometrial endometrioid carcinoma. Am J Surg Pathol 41:896–905. https://doi.org/10.1097/pas.0000000000000856
Sanci M, Güngördük K, Gülseren V et al (2017) MELF pattern for predicting lymph node involvement and survival in grade I-II endometrioid-type endometrium cancer. Int J Gynecol Pathol:1. https://doi.org/10.1097/pgp.0000000000000370
Stewart CJR, Little L (2009) Immunophenotypic features of MELF pattern invasion in endometrial adenocarcinoma: evidence for epithelial-mesenchymal transition. Histopathology 55:91–101. https://doi.org/10.1111/j.1365-2559.2009.03327.x
Stewart CJ, Crook ML (2010) Galectin-3 expression in uterine endometrioid adenocarcinoma. Int J Gynecol Pathol 29:555–561. https://doi.org/10.1097/pgp.0b013e3181e4ee4ea
Petty AJ, Yang Y (2017) Tumor-associated macrophages: implications in cancer immunotherapy. Immunotherapy 9:289–302. https://doi.org/10.2217/imt-2016-0135
Quail DF, Joyce JA (2013) Microenvironmental regulation of tumor progression and metastasis. Nat Med 19:1423–1437. https://doi.org/10.1038/nm.3394
Shurin MR et al. (2016) Tumor Immunoenvironment. Springer, S.l.
Zinovkin DA, Pranjol MZI, Petrenyov DR et al (2017) The potential roles of MELF-pattern, microvessel density, and vegf expression in survival of patients with endometrioid endometrial carcinoma: a morphometrical and immunohistochemical analysis of 100 cases. Journal of Pathology and Translational Medicine 51:456–462. https://doi.org/10.4132/jptm.2017.07.19
Zinovkin D, Pranjol MZI (2016) Tumor-infiltrated lymphocytes, macrophages, and dendritic cells in endometrioid adenocarcinoma of corpus uteri as potential prognostic factors. Int J Gynecol Cancer 26:1207–1212. https://doi.org/10.1097/igc.0000000000000758
Dunn GP, Bruce AT, Ikeda H et al (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3:991–998. https://doi.org/10.1038/ni1102-991
Seager RJ, Hajal C, Spill F et al (2017) Dynamic interplay between tumour, stroma and immune system can drive or prevent tumour progression. Convergent Science Physical Oncology 3:034002. https://doi.org/10.1088/2057-1739/aa7e86
Maluf PJ, Michelin MA, Etchebehere RM et al (2008) T lymphocytes (CD3) may participate in the recurrence of cervical intraepithelial neoplasia grade III. Arch Gynecol Obstet 278:525–530. https://doi.org/10.1007/s00404-008-0621-8
Brand A, Singer K, Koehl GE et al (2016) LDHA-associated lactic acid production blunts tumor immunosurveillance by t and nk cells. Cell Metab 24:657–671. https://doi.org/10.1016/j.cmet.2016.08.011
Dietl K, Renner K, Dettmer K et al (2009) Lactic acid and acidification inhibit tnf secretion and glycolysis of human monocytes. J Immunol 184:1200–1209. https://doi.org/10.4049/jimmunol.0902584
Spaner D, Bahlo A (2011) B lymphocytes in cancer immunology. In: Medin J, Fowler D (eds) Experimental and applied immunotherapy. Humana Press, Totowa, NJ
Stakheeva M, Riabov V, Mitrofanova I et al (2017) Role of the immune component of tumor microenvironment in the efficiency of cancer treatment: perspectives for the personalized therapy. Curr Pharm Des 23:1–20. https://doi.org/10.2174/1381612823666170714161703
Pegram HJ, Haynes NM, Smyth MJ et al (2010) Characterizing the anti-tumor function of adoptively transferred NK cells in vivo. Cancer Immunol Immunother 59:1235–1246. https://doi.org/10.1007/s00262-010-0848-7
Levy E, Bianchini M, Euw EV et al (2008) Human leukocyte antigen-E protein is overexpressed in primary human colorectal cancer. Int J Oncol. https://doi.org/10.3892/ijo.32.3.633
Yuan A, Chen JJW, Yang PC (2008) Pathophysiology of tumor-associated macrophages. Adv Clin Chem:199–223. https://doi.org/10.1016/s0065-2423(07)00008-x
Biswas SK, Sica A, Lewis CE (2008) Plasticity of macrophage function during tumor progression: regulation by distinct molecular mechanisms. J Immunol 180:2011–2017. https://doi.org/10.4049/jimmunol.180.4.2011
Slayton WB, Hu Z (2010) Bone marrow stroma and the leukemic microenvironment. In: Tumor microenvironment, pp 99–133. https://doi.org/10.1002/9780470669891.ch6
Ha SY, Yeo S-Y, Xuan Y-H, Kim S-H (2014) The prognostic significance of cancer-associated fibroblasts in esophageal squamous cell carcinoma. PLoS One 9:e99955. https://doi.org/10.1371/journal.pone.0099955
Zheng X, Turkowski K, Mora J et al (2017) Redirecting tumor-associated macrophages to become tumoricidal effectors as a novel strategy for cancer therapy. Oncotarget 8:48436–48452. https://doi.org/10.18632/oncotarget.17061
Shurin MR, Salter RD (2009) Dendritic cells in cancer. Springer, New York, NY
Tashireva LA, Perelmuter VM, Manskikh VN, et al (2017) Types of immune-inflammatory responses as a reflection of cell–cell interactions under conditions of tissue regeneration and tumor growth. Biochem Mosc 82:542–555. https://doi.org/10.1134/s0006297917050029
Pasqual G, Chudnovskiy A, Tas JMJ et al (2018) Monitoring T cell–dendritic cell interactions in vivo by intercellular enzymatic labelling. Nature 553:496–500. https://doi.org/10.1038/nature25442
Janco JMT, Lamichhane P, Karyampudi L, Knutson KL (2015) Tumor-infiltrating dendritic cells in cancer pathogenesis. J Immunol 194:2985–2991. https://doi.org/10.4049/jimmunol.1403134
Becht E, Giraldo NA, Germain C et al (2016) Immune contexture, Immunoscore, and malignant cell molecular subgroups for prognostic and Theranostic classifications of cancers. Advances in Immunology Tumor Immunology:95–190. https://doi.org/10.1016/bs.ai.2015.12.002
Fridman WH, Pagès F, Sautès-Fridman C, Galon J (2012) The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 12:298–306. https://doi.org/10.1038/nrc3245
Becht E, Giraldo NA, Dieu-Nosjean M-C et al (2016) Cancer immune contexture and immunotherapy. Curr Opin Immunol 39:7–13. https://doi.org/10.1016/j.coi.2015.11.009
Jiang H, Hegde S, Denardo DG (2017) Tumor-associated fibrosis as a regulator of tumor immunity and response to immunotherapy. Cancer Immunol Immunother 66:1037–1048. https://doi.org/10.1007/s00262-017-2003-1